论文部分内容阅读
血小板的黏附、活化、聚集在急性冠状动脉综合征及经皮冠状动脉介入(PCI)治疗的病理生理进程中占主导地位。阿司匹林和血小板腺苷二磷酸P2Y12受体抑制剂(氯吡格雷、替格瑞洛等)是临床应用的经典抗血小板药物,同时也是急性冠状动脉综合征与PCI的基石。随着对抗血小板领域研究的不断拓展,个体对抗血小板药物治疗存在明显的反应性差异,这种差异与冠状动脉支架术后复合终点事件显著相关。因此,精准评估PCI患者在接受抗血小板药物治疗后血小板反应性的情况,给予规范化、个体化的临床治疗方案以减少死亡、非致死性心肌梗死、血栓事件及出血事件的发生,对改善患者远期预后具有深远的临床意义。
Platelet adhesion, activation, aggregation predominates in the pathophysiological processes of acute coronary syndrome and percutaneous coronary intervention (PCI). Aspirin and platelet adenosine diphosphate P2Y12 receptor inhibitors (clopidogrel, ticagrelor, etc.) are the classical antiplatelet agents for clinical use and are also the cornerstone of acute coronary syndrome and PCI. With the continuous expansion of the research in the field of anti-platelet, there was a significant difference in individual reactivity to platelet therapy, which is significantly related to the composite end point after coronary stent. Therefore, accurate evaluation of patients with PCI after receiving antiplatelet drug therapy platelet reactivity, to give standardized and individualized clinical treatment programs to reduce death, non-fatal myocardial infarction, thrombotic events and bleeding events, to improve patients far Prognosis has far-reaching clinical significance.